-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Zymeworks, Raises Price Target to $39

Benzinga·11/13/2026 13:44:55
Listen to the news
Citizens analyst Reni Benjamin maintains Zymeworks (NASDAQ:ZYME) with a Market Outperform and raises the price target from $32 to $39.